研究文章

免疫治疗时代寡转移非小细胞肺癌局部巩固放疗的研究进展

摘要

寡转移非小细胞肺癌包括初诊寡转移、系统治疗后寡残留及治疗期间寡进展等状态,局部治疗的目的与适用证据并不相同。本文综述局部巩固放疗与免疫治疗衔接的生物学依据、前瞻性临床证据、患者选择及安全性。免疫治疗广泛应用前的小样本随机Ⅱ期研究显示,全病灶局部巩固治疗可延长无进展生存,部分研究还观察到总生存获益,但局部治疗可包含手术。免疫治疗背景下的NRG-LU002会议摘要未显示常规增加局部巩固治疗可改善无进展或总生存,且≥3级肺炎性反应更多。2026年LONESTAR试验会议结果同样未发现总体人群或寡转移亚组的生存获益,但其局部治疗并不要求覆盖所有病灶。寡残留单臂研究及寡进展随机研究分别为不同疾病状态提供线索,不能相互替代。未来需要按疾病状态与病灶分布分层,在随机试验中同时评价生存、局部控制、生活质量与毒性。

关键词

寡转移;非小细胞肺癌;局部巩固放疗;立体定向放疗;免疫检查点抑制剂

参考

Dingemans A M C, Hendriks L E L, Berghmans T, et al.Definition of synchronous oligometastatic non-small celllung cancer: a consensus report[J]. J Thorac Oncol, 201 9,14(12): 2109-2119. DOI: 10.1016/j.jtho.2019.07.025.

Guckenberger M, Lievens Y, Bouma A B, et al. Character-isation and classification of oligometastatic disease: a Eu-ropean Society for Radiotherapy and Oncology and Europ-87亚洲临床医学杂志·第09卷·第11期·2026年11月ean Organisation for Research and Treatment of Cancer consensus recommendation[J]. Lancet Oncol, 2020, 21(1):e18-e28. DOI: 10.1016/S1470-2045(19)30718-1.

Iyengar P, All S, Berry M F, et al. Treatment of oligometa-static non-small cell lung cancer: an ASTRO/ESTRO clin-ical practice guideline[J]. Pract Radiat Oncol, 2023, 13(5-): 393-412. DOI: 10.1016/j.prro.2023.04.004.

Gomez D R, Blumenschein G R Jr, Lee J J, et al. Local consolidative therapy versus maintenance therapy or observ-ation for patients with oligometastatic non-small-cell lungcancer without progression after first-line systemic therap-y: a multicentre, randomised, controlled, phase 2 study[J].Lancet Oncol, 2016, 17(12): 1672-1682. DOI: 10.1016/S1-470-2045(16)30532-0.

Gomez D R, Tang C, Zhang J, et al. Local consolidativetherapy vs maintenance therapy or observation for patientswith oligometastatic non-small-cell lung cancer: long-termresults of a multi-institutional, phase II, randomized stud-y[J]. J Clin Oncol, 2019, 37(18): 1558-1565. DOI: 10.120-0/JCO.19.00201.

Iyengar P, Wardak Z, Gerber D E, et al. Consolidative ra-diotherapy for limited metastatic non-small-cell lung can-cer: a phase 2 randomized clinical trial[J]. JAMA Oncol,2018, 4(1): e173501. DOI: 10.1001/jamaoncol.2017.3501.

Bauml J M, Mick R, Ciunci C, et al. Pembrolizumab aftercompletion of locally ablative therapy for oligometastaticnon-small cell lung cancer: a phase 2 trial[J]. JAMA Onc-ol, 2019, 5(9): 1283-1290. DOI: 10.1001/jamaoncol.2019.1-449.

Theelen W S M E, Peulen H M U, Lalezari F, et al. Effectof pembrolizumab after stereotactic body radiotherapy vspembrolizumab alone on tumor response in patients withadvanced non-small cell lung cancer: results of the PEM-BRO-RT phase 2 randomized clinical trial[J]. JAMA Onc-ol, 2019, 5(9): 1276-1282. DOI: 10.1001/jamaoncol.2019.1-478.

Theelen W S M E, Chen D, Verma V, et al. Pembrolizumabwith or without radiotherapy for metastatic non-small-celllung cancer: a pooled analysis of two randomised trials[J].Lancet Respir Med, 2021, 9(5): 467-475. DOI: 10.1016/S-2213-2600(20)30391-X.

Iyengar P, Hu C, Gomez D R, et al. NRG-LU002: randomized phase II/III trial of maintenance systemic therapy versus local consolidative therapy plus maintenance systemic therapy for limited metastatic non-small cell lung cancer[J]. J Clin Oncol, 2024, 42(16_suppl): 8506. DOI: 10.1200/JCO.2024.42.16_ suppl.8506. (会议摘要)

Chen H, Yu L, Liang F, et al. Consolidative stereotacticradiotherapy for oligo-residual non-small cell lung canc-er after first-line chemoimmunotherapy: a single-arm, phase 2 trial from China[J]. PLoS Med, 2025, 22(8): e1004-680. DOI: 10.1371/journal.pmed.1004680.

Tsai C J, Yang J T, Shaverdian N, et al. Standard-of-caresystemic therapy with or without stereotactic body radio-therapy in patients with oligoprogressive breast canceror non-small-cell lung cancer (CURB): an open-label, ra-ndomised, controlled, phase 2 study[J]. Lancet, 2024, 403(10422): 171-182. DOI: 10.1016/S0140-6736(23)01857-3.

Vanpouille-Box C, Alard A, Aryankalayil M J, et al. DNA exonuclease Trex1 regulates radiotherapy-induced tu-mour immunogenicity[J]. Nat Commun, 2017, 8: 15618.DOI: 10.1038/ncomms15618.

Semenkovich N P, Badiyan S N, Samson P P, et al. Pre-r-adiotherapy ctDNA liquid biopsy for risk stratificationof oligometastatic non-small cell lung cancer[J]. NPJ Pr-ecis Oncol, 2023, 7(1): 100. DOI: 10.1038/s41698-023-00-440-6.

Kroeze S G C, Pavic M, Stellamans K, et al. Metastases--directed stereotactic body radiotherapy in combinationwith targeted therapy or immunotherapy: systematic revi-ew and consensus recommendations by the EORTC-EST-RO OligoCare consortium[J]. Lancet Oncol, 2023, 24(3):e121-e132. DOI: 10.1016/S1470-2045(22)00752-5.

Cantor D J, Davis C, Ciunci C, et al. Brief report: long-t-erm follow-up of adjuvant pembrolizumab after locallyablative therapy for oligometastatic NSCLC[J]. JTO ClinRes Rep, 2024, 5(6): 100667. DOI: 10.1016/j.jtocrr.2024.1-00667.

International Association for the Study of Lung Cancer.Local consolidative therapy does not improve survival after dual immunotherapy in metastatic NSCLC[EB/OL].(2026-09-12)[2026-09-29]. https://www.iaslc.org/iaslc-new-s/press-release/local-consolidative-therapy-does-not-improve-survival-after-dual.88

Refbacks

  • 当前没有refback。
版权所有(c)2026 一龙 刘, 欢 刘, 镭 刘, 力 张
Creative Commons License
此作品已接受知识共享署名-非商业性使用 4.0国际许可协议的许可。